Klf4 was first identified as a tumor suppressor, owing to frequent loss of Klf4 expression in gastric, colon, esophageal, bladder and lung cancer, as well as in pancreatic ductal carcinoma (16–18). Here, KLF4 is linked to pancreatic ductal adenocarcinoma.